Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00251680 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Lowering Therapy.
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
NCT00251680 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 400 participants.
The verdict
NCT00251680, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the efficacy of lapaquistat acetate, once daily (QD), taken with established lipid-lowering therapy in subjects with type 2 diabetes mellitus.
Interventions
- DRUG Lapaquistat acetate and lipid-lowering therapy
- DRUG Lipid-lowering therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2005-10 |
| Est. Completion | 2007-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00251680
The ClinicalTrials.gov registry entry for NCT00251680 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lapaquistat acetate and lipid-lowering therapy is the first listed.
NCT00251680 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00251680 about?
NCT00251680 is a clinical study titled "Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Lowering Therapy.". The purpose of the study is to determine the efficacy of lapaquistat acetate, once daily (QD), taken with established lipid-lowering therapy in subjects with type 2 diabetes mellitus.
What is the current status of trial NCT00251680?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2005-10. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00251680?
The interventions under investigation include: Lapaquistat acetate and lipid-lowering therapy (DRUG), Lipid-lowering therapy (DRUG).
Who is sponsoring clinical trial NCT00251680?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.